Psychosocial Benefit Seen With Probiotic, Peanut Oral Immunotx

This article originally appeared here.
Share this content:
Psychosocial Benefit Seen With Probiotic, Peanut Oral Immunotx
Psychosocial Benefit Seen With Probiotic, Peanut Oral Immunotx

FRIDAY, Nov. 17, 2017 (HealthDay News) -- Probiotic and peanut oral immunotherapy (PPOIT) has a sustained beneficial effect on psychosocial impact of food allergy after end-of-treatment, according to a study published online Oct. 20 in Allergy.

Audrey Dunn Galvin, Ph.D., from University College Cork in Ireland, and colleagues evaluated the impact of PPOIT on health-related quality-of-life (HRQL) among 51 participants in a randomized controlled trial. Participants completed questionnaires at pre-treatment, end-of-treatment, and three-months after end-of-treatment. Forty-two participants completed 12-month surveys.

The researchers found that PPOIT was associated with significant improvement in Food Allergy Quality of Life Questionnaire (FAQLQ; P = 0.02), with the mean difference at three months post-treatment (P = 0.05) and 12 months post-treatment (P = 0.005) exceeding the clinically important difference. Similarly, there were significant mean differences in Food Allergy Independent Measure (FAIM) at three months (P = 0.03) and 12 months (P = 0.04). Among the placebo group, post-treatment FAQLQ and FAIM remained unchanged from pre- to post-treatment.

"Treatment was not associated with reduced HRQL relative to baseline in either PPOIT or placebo groups, indicating that PPOIT was well tolerated and psychological well-being was not negatively impacted," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »